$224 Million is the total value of Fairmount Funds Management LLC's 14 reported holdings in Q2 2020. The portfolio turnover from Q1 2020 to Q2 2020 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ACAD | Sell | ACADIA PHARMACEUTICALS INC | $28,380,000 | +11.3% | 585,517 | -3.0% | 12.66% | -18.2% |
| INSM | Sell | INSMED INC | $27,837,000 | +70.1% | 1,010,797 | -1.0% | 12.42% | +25.1% |
| ZGNX | ZOGENIX INC | $26,250,000 | +9.2% | 971,875 | 0.0% | 11.71% | -19.7% | |
| FOLD | Buy | AMICUS THERAPEUTICS INC | $22,701,000 | +83.3% | 1,505,395 | +12.3% | 10.12% | +34.8% |
| AXSM | Buy | AXSOME THERAPEUTICS INC | $17,781,000 | +59.4% | 216,098 | +14.0% | 7.93% | +17.2% |
| IOVA | Buy | IOVANCE BIOTHERAPEUTICS INC | $16,577,000 | +12.7% | 603,890 | +22.9% | 7.39% | -17.1% |
| ALLK | ALLAKOS INC | $12,839,000 | +61.5% | 178,662 | 0.0% | 5.73% | +18.8% | |
| NLTX | Sell | NEOLEUKIN THERAPEUTICS INC | $12,783,000 | +38.7% | 770,073 | -4.9% | 5.70% | +2.0% |
| KPTI | Buy | KARYOPHARM THERAPEUTICS INC | $12,356,000 | +14.4% | 652,351 | +16.0% | 5.51% | -15.9% |
| Sell | TRILLIUM THERAPEUTICS INC | $11,999,000 | +63.4% | 1,483,181 | -18.4% | 5.35% | +20.1% | |
| ARGX | Sell | ARGENX SEsponsored adr | $11,363,000 | +12.5% | 50,450 | -34.2% | 5.07% | -17.2% |
| AMRN | Buy | AMARIN CORP PLCspons adr new | $9,710,000 | +178.5% | 1,403,237 | +61.0% | 4.33% | +104.8% |
| ENTA | ENANTA PHARMACEUTICALS INC | $8,533,000 | -2.4% | 169,949 | 0.0% | 3.81% | -28.2% | |
| KNSA | KINIKSA PHARMACEUTICALS LTD | $5,099,000 | +64.6% | 200,125 | 0.0% | 2.27% | +21.0% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-08-04
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ARGENX SE | 16 | Q3 2023 | 9.3% |
| AXSOME THERAPEUTICS INC | 15 | Q3 2023 | 24.6% |
| INSMED INC | 12 | Q3 2022 | 15.0% |
| ACADIA PHARMACEUTICALS INC | 12 | Q3 2022 | 15.5% |
| IOVANCE BIOTHERAPEUTICS INC | 12 | Q3 2022 | 9.4% |
| COGENT BIOSCIENCES INC | 12 | Q3 2023 | 7.2% |
| ENANTA PHARMACEUTICALS INC | 12 | Q3 2022 | 9.6% |
| ALLAKOS INC | 12 | Q3 2022 | 7.4% |
| AMARIN CORP PLC | 12 | Q3 2022 | 10.9% |
| VERONA PHARMA PLC | 12 | Q2 2023 | 11.9% |
View Fairmount Funds Management LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Aeglea BioTherapeutics, Inc. | June 30, 2023 | 17,230,540 | 20.0% |
| Olema Pharmaceuticals, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| CATABASIS PHARMACEUTICALS INC | June 17, 2021 | 4,092,166 | 5.3% |
| MIRAGEN THERAPEUTICS, INC. | January 05, 2021 | 967,671 | 20.0% |
| Unum Therapeutics Inc. | July 10, 2020 | 7,482,460 | 20.0% |
View Fairmount Funds Management LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-04-25 |
| SC 13D/A | 2024-04-25 |
| 4 | 2024-04-01 |
| 4 | 2024-04-01 |
| 4 | 2024-04-01 |
| 4 | 2024-04-01 |
| SC 13D/A | 2024-04-01 |
| SC 13D/A | 2024-04-01 |
| SC 13D/A | 2024-04-01 |
| SC 13D/A | 2024-04-01 |
View Fairmount Funds Management LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.